Jentadueto

How to order Jentadueto

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Jentadueto on Prescriptsy

Jentadueto is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Jentadueto is a prescription-only combination medicine used to treat type 2 diabetes in adults. Each tablet contains linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride, a biguanide.

The two active ingredients work through complementary mechanisms to lower blood glucose levels. Jentadueto is prescribed when metformin alone does not achieve adequate blood sugar control.

It is manufactured by Boehringer Ingelheim, available in two strengths (2.5 mg/850 mg and 2.5 mg/1000 mg), and is classified as a prescription-only medicine (POM) in the United Kingdom.

Type 2 diabetes affects approximately 4.3 million people in the United Kingdom, with around 90% of all diabetes diagnoses being type 2.

The condition arises from a combination of insulin resistance and relative insulin deficiency, leading to chronically elevated blood glucose that, over time, damages blood vessels and nerves throughout the body.

The complications of poorly controlled type 2 diabetes include coronary heart disease, stroke, chronic kidney disease, retinopathy, neuropathy, and diabetic foot disease.

Effective blood sugar management, combined with cardiovascular risk reduction, significantly reduces the burden of these complications.

This page provides a comprehensive clinical overview of Jentadueto, covering how it works, its clinical evidence base, dosage guidance, potential side effects, safety warnings, and how to obtain a prescription in the United Kingdom.

Important safety information about Jentadueto

Before reading further, note these essential safety points about Jentadueto.

• Jentadueto is a prescription-only medicine requiring medical supervision.
• It must not be used in type 1 diabetes, diabetic ketoacidosis, or severe kidney impairment (eGFR below 30).
• Regular kidney function monitoring is essential.
• Metformin must be temporarily stopped before CT scans with iodinated contrast and before general anaesthesia.
• Seek immediate medical help for severe persistent abdominal pain, which may indicate pancreatitis.
• Stop Jentadueto temporarily during any acute illness causing dehydration.

Understanding type 2 diabetes

Type 2 diabetes develops when the body's cells become resistant to the effects of insulin and the pancreas cannot produce enough insulin to overcome this resistance.

Insulin is essential for moving glucose from the bloodstream into cells for energy. When this process fails, glucose accumulates in the blood, producing persistent hyperglycaemia.

Over time, elevated blood glucose damages both small blood vessels (causing retinopathy, nephropathy, and neuropathy) and large blood vessels (increasing the risk of heart attack, stroke, and peripheral arterial disease).

Risk factors for type 2 diabetes include obesity (particularly central adiposity), physical inactivity, a family history of diabetes, age over 40 (or over 25 in South Asian, Black African, and African-Caribbean populations), a history of gestational diabetes, and polycystic ovary syndrome.

The rising prevalence across the UK is closely linked to increasing rates of obesity.

Management follows the NICE NG28 stepwise approach.

Lifestyle modifications form the foundation: a balanced diet, regular physical activity (at least 150 minutes per week of moderate-intensity exercise), and weight loss where appropriate.

Metformin is recommended as first-line pharmacological therapy. When metformin alone does not achieve the target HbA1c, a second agent is added.

Linagliptin is one of several options at this stage, alongside sulfonylureas, pioglitazone, SGLT2 inhibitors, and GLP-1 receptor agonists.

How Jentadueto works: mechanism of action

Jentadueto combines two medicines that address different pathophysiological defects in type 2 diabetes.

Metformin hydrochloride suppresses excessive hepatic glucose output by activating AMP-activated protein kinase (AMPK), which reduces both gluconeogenesis and glycogenolysis in the liver.

It also enhances insulin sensitivity in skeletal muscle and other peripheral tissues, improving glucose uptake. Metformin has a modest effect on delaying intestinal glucose absorption.

It does not stimulate insulin secretion, so it carries a low risk of hypoglycaemia when used alone and is generally weight-neutral.

Linagliptin selectively inhibits the enzyme DPP-4, which normally breaks down the incretin hormones GLP-1 and GIP within minutes of their release from the gut following food intake.

By blocking DPP-4, linagliptin extends the half-life of these incretins. GLP-1 stimulates insulin secretion and suppresses glucagon release from the pancreas, both in a glucose-dependent manner.

GIP similarly enhances postprandial insulin secretion.

Because these effects are glucose-dependent, linagliptin promotes insulin release only when blood sugar is elevated and has minimal effect when glucose levels are normal, resulting in a low hypoglycaemia risk.

A key pharmacological distinction of linagliptin from other DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin, alogliptin) is its predominantly non-renal elimination.

Approximately 85% of linagliptin is excreted unchanged via the bile and faeces, with only about 5% appearing in the urine.

This unique elimination pathway means that linagliptin does not accumulate in patients with reduced kidney function and requires no dose adjustment at any level of renal impairment.

However, the metformin component of Jentadueto retains all the usual renal precautions.

Clinical evidence and UK prescribing guidance

The combination of linagliptin and metformin has been evaluated in several clinical trials.

Adding linagliptin to ongoing metformin therapy reduced HbA1c by approximately 0.6 to 0.7 percentage points (6 to 8 mmol/mol) compared with metformin alone.

The combination was weight-neutral, with a low incidence of hypoglycaemia comparable to placebo.

The CARMELINA (Cardiovascular and Renal Microvascular Outcome Study with Linagliptin) trial demonstrated that linagliptin did not increase the risk of major adverse cardiovascular events, heart failure hospitalisation, or renal outcomes compared with placebo in patients with type 2 diabetes at high cardiovascular and renal risk.

The CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride) trial showed that linagliptin had similar cardiovascular safety to the sulfonylurea glimepiride but with significantly fewer hypoglycaemic episodes and no weight gain.

NICE NG28 lists DPP-4 inhibitors as one option for dual therapy with metformin. The choice among second-line agents depends on individual patient factors.

SGLT2 inhibitors are preferred for patients with established cardiovascular disease, heart failure, or chronic kidney disease because of their proven cardiorenal protective benefits.

DPP-4 inhibitors such as linagliptin remain appropriate for patients who prioritise a low risk of hypoglycaemia and weight gain, particularly when SGLT2 inhibitors are contraindicated or not tolerated.

Jentadueto compared with other combination diabetes medicines

Several DPP-4 inhibitor/metformin combinations are available in the UK. Janumet (sitagliptin/metformin), Eucreas (vildagliptin/metformin), and Komboglyze (saxagliptin/metformin) are alternatives to Jentadueto.

The DPP-4 inhibitors in these products have broadly similar efficacy for HbA1c reduction.

The distinguishing feature of linagliptin is its non-renal elimination, which simplifies prescribing decisions in patients with fluctuating renal function.

However, the metformin component of all these combinations still requires renal monitoring.

SGLT2 inhibitor/metformin combinations (empagliflozin/metformin, dapagliflozin/metformin) offer additional benefits including weight loss, blood pressure reduction, and cardiovascular and renal protection.

GLP-1 receptor agonists produce greater HbA1c reduction and weight loss than DPP-4 inhibitors but are administered by injection (with the exception of oral semaglutide) and are generally used at a later treatment stage or when weight management is a clinical priority.

Dosage and administration

Jentadueto is taken twice daily with meals, one tablet with breakfast and one with the evening meal. Swallow the tablets whole with water.

Two strengths are available: 2.5 mg linagliptin/850 mg metformin and 2.5 mg linagliptin/1000 mg metformin.

The choice of strength depends on the dose of metformin the patient was previously taking or tolerating during titration. The total daily dose of linagliptin is 5 mg.

Renal function monitoring is essential.

Check eGFR before starting, annually in patients with normal renal function, and every 3 to 6 months in patients over 65 or with declining function.

Jentadueto should not be initiated if eGFR is below 45 and must be stopped if eGFR falls below 30.

In patients with eGFR 30 to 44, metformin doses above 1000 mg per day are not recommended, and individual component tablets should be used.

During acute illness involving dehydration, temporarily stop Jentadueto and seek medical advice. Restart only when fully recovered and renal function is confirmed as stable.

Side effects of Jentadueto

Gastrointestinal effects

The most common side effects are gastrointestinal, attributable to metformin: nausea, vomiting, diarrhoea, abdominal discomfort, bloating, flatulence, and metallic taste.

These typically occur early in treatment and often settle over weeks. Taking the tablets with food and titrating the dose gradually helps minimise these effects.

Other common side effects

Nasopharyngitis, cough, and headache have been reported with linagliptin at rates similar to placebo. Hypoglycaemia is rare with Jentadueto alone but may occur when combined with a sulfonylurea or insulin.

Rare and serious side effects

Acute pancreatitis has been reported with DPP-4 inhibitors. Seek urgent medical attention for severe, persistent abdominal pain. If pancreatitis is confirmed, discontinue Jentadueto permanently.

Bullous pemphigoid has been reported rarely. Lactic acidosis is an extremely rare but life-threatening risk of metformin, occurring almost exclusively in patients with predisposing factors.

Symptoms include nausea, vomiting, rapid breathing, abdominal pain, and muscle cramps. Call 999 immediately. Long-term metformin use may reduce vitamin B12 absorption.

When to seek urgent help

Contact your GP or call NHS 111 for persistent gastrointestinal symptoms, fatigue, or tingling in the extremities.

Call 999 or attend A&E for severe abdominal pain, difficulty breathing, swelling of the face or throat, or signs of severe hypoglycaemia.

Report suspected reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Jentadueto must not be used in type 1 diabetes, diabetic ketoacidosis, severe renal impairment (eGFR below 30), hepatic insufficiency, conditions causing tissue hypoxia (decompensated heart failure, respiratory failure), chronic alcohol abuse, or known hypersensitivity to any component.

Monitoring and interactions

Renal function, HbA1c, and vitamin B12 should be monitored as outlined above. Drug interactions include cimetidine (increased metformin levels), glucocorticoids (hyperglycaemia), diuretics (renal impairment risk), and rifampicin (potential reduction in linagliptin exposure). Excessive alcohol increases the risk of lactic acidosis.

Pregnancy and breastfeeding

Jentadueto is not recommended during pregnancy or breastfeeding. Women planning a pregnancy should transition to insulin under specialist guidance.

Sick day rules

Stop Jentadueto during any acute illness causing dehydration. Restart only when recovered and renal function is stable. Your diabetes team should provide personalised sick day instructions.

How to get Jentadueto in the UK

Jentadueto is a prescription-only medicine. Your GP, diabetologist, or an authorised online prescriber registered with the GPhC can prescribe it after a clinical assessment.

The NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Patients with diabetes in England can obtain a medical exemption certificate from their GP, providing free prescriptions for all medicines.

Living with type 2 diabetes: lifestyle alongside Jentadueto

Medication works best when combined with sustained lifestyle changes.

Follow a balanced diet based on whole grains, vegetables, lean protein, and healthy fats, limiting refined sugars and processed foods.

Aim for at least 150 minutes of moderate-intensity physical activity per week. If overweight, losing 5 to 10% of body weight can meaningfully improve blood sugar control.

Limit alcohol to no more than 14 units per week and stop smoking if applicable, as smoking significantly amplifies cardiovascular risk in diabetes.

Attend all follow-up appointments including annual diabetes reviews, retinal screening, and foot examinations.

Sources

• Jentadueto, Summary of Product Characteristics (EMC)
• Linagliptin with metformin, British National Formulary (BNF)
• NICE NG28: Type 2 diabetes in adults: management
• Type 2 diabetes, NHS
• Diabetes UK
• MHRA Yellow Card Scheme